EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis

Stock Information for EDAP TMS S.A.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About EDAP TMS S.A.

EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting
EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results
EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024
EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2023 Revenues
EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis
EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements
EDAP Appoints Ken Mobeck, Global Chief Financial Officer, and Francois Dietsch, Global Chief Accounting Officer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.